GMP-Abemaciclib (LY2835219) CAS 1231929-97-7
abemaciclibAn orally available cyclin-dependent kinase (CDK) inhibitor that targets the CDK4 (cyclin D1) and CDK6 (cyclin D3) cell cycle pathway, with potential antineoplastic activity. Abemaciclib specifically inhibits CDK4 and 6, thereby inhibiting retinoblastoma (Rb) protein phosphorylation in early G1.
| Abemaciclib (LY2835219) | |||
| N-(4-bromo-2,6-difluoro-phenyl)-N’-isopropyl-acetamidine | 1231930-29-2 | ＞98% | |
| Int 1 | 1H-BenziMidazole,6-(2-chloro-5-fluoro-4-pyriMidinyl)-4-fluoro-2-Methyl-1-(1-Methylethyl) | 1231930-42-9 | ＞98% |
| Int 2 | 5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-amine | 1180132-17-5 | ＞98% |
| Int 3 | 4-fluoro-1-isopropyl-2-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-benzo[d]imidazole | 1231930-37-2 | ＞98% |
| Int 4 | 6-Bromo-4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazole | 1231930-33-8 | ＞98% |
